|
|
福島県立医科大学学術成果リポジトリ = Fukushima Medical University Repository >
福島医学会 = The Fukushima Society of Medical Science >
Fukushima Journal of Medical Science >
Vol.56 (2010) >
このアイテムの引用には次の識別子を使用してください:
http://ir.fmu.ac.jp/dspace/handle/123456789/256
|
| タイトル: | Attenuation of ischemic myocardial injury and dysfunction by cardiac fibroblast-derived factor(s) |
| その他のタイトル: | Cardio protection by cardiac fibroblasts |
| 著者: | Nakazato, Kazuhiko
Naganuma, Wakako
Ogawa, Kazuei
Yaoita, Hiroyuki
Mizuno, Shinya
Nakamura, Toshikazu
Maruyama, Yukio |
| 学内所属: | 循環器・血液内科学講座 |
| 誌名/書名: | Fukushima Journal of Medical Science |
| 巻: | 56 |
| 号: | 1 |
| 開始ページ: | 1 |
| 終了ページ: | 16 |
| 発行日: | 2010年6月 |
| 抄録: | Fibroblasts, the majority of non-cardiomyocytes in the heart, are known to release several kinds of substances such as cytokines and hormones that affect cell and tissue functions. We hypothesized that undefined substance (s) derived from cardiac fibroblasts may have the potential to protect against ischemic myocardium. To assess our hypothesis, using rats, we investigated: (1) the effect of cardiac fibroblast-conditioned medium (CM) on the viability of hypoxic cardiomyocytes in vitro, (2) the effect of CM on left ventricular (LV) function in global ischemia-reperfusion in an ex vive model, (3) the mechanism underlying cardioprotection by CM. Seventy-two hours after starting a hypoxic culture, the viability of cardiomyocytes was higher (P < 0.05) in the CM treated group (41.4%) compared to the control (20.5%). In Langendorff's preparation, 30 min after ischemia-reperfusion, LV end-diastolic pressure was lower, and LV developed pressure and -LVdP/dt were higher (P < 0.01 or P < 0.05) in the CM group than in the control, although coronary flow did not differ between the two groups. Pretreatment with a protein kinase C inhibitor or a mitochondrial ATP-sensitive K+ channel blocker attenuated these changes of LV function in the CM group. Such cardioprotection was achieved by a fraction of the CM having a molecular weight (MW) > 50,000, but not by that of the CM with a lower MW. In addition, a specific antibody against hepatocyte growth factor (HGF, MW is 84,000) did not reduce the cardioprotection afforded by CM. There may be an unknown cardioprotective substance other than HGF in rats, which mimics ischemic preconditioning and has MW > 50,000. |
| 出版者: | The Fukushima Society of Medical Science |
| 出版者（異表記）: | 福島医学会 |
| 本文の言語: | eng |
| このページのURI: | http://ir.fmu.ac.jp/dspace/handle/123456789/256 |
| 本文URL: | http://ir.fmu.ac.jp/dspace/bitstream/123456789/256/1/FksmJMedSci_56_p1.pdf |
| ISSN: | 0016-2590
2185-4610 |
| DOI: | 10.5387/fms.56.1 |
| PubMed番号: | 21485651 |
| 異版(出版者版等): | http://dx.doi.org/10.5387/fms.56.1 |
| 権利情報: | © 2010 The Fukushima Society of Medical Science |
| 出現コレクション: | Vol.56 (2010)
|
このリポジトリに保管されているアイテムは、他に指定されている場合を除き、著作権により保護されています。
|
